Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-009848
Filing Date
2025-01-28
Accepted
2025-01-28 16:30:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 11077
  Complete submission text file 0000950170-25-009848.txt   12883
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Subject) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93208 | Film No.: 25564630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address BLOCK A, APT.12 IL-PIAZZETTA, TOWER ROAD SLIEMA O1 SLM1605
Business Address BLOCK A, APT.12 IL-PIAZZETTA, TOWER ROAD SLIEMA O1 SLM1605 44 7557 251 563
Apeiron Investment Group Ltd. (Filed by) CIK: 0001845711 (see all company filings)

EIN.: 000000000 | State of Incorp.: O1 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A